Purpose: Osteoarthritis (OA) affects approximately ten percent of all Canadians and is the leading cause of physical disability and impaired quality of life in North America. Despite the prevalence and severity of this degenerative joint disease, its underlying pathological mechanisms are not well understood. Recently, our lab established a surgical rodent model of OA in order to study gene expression changes in degenerating articular cartilage. We found that transforming growth factor alpha (TGF alpha) gene expression was upregulated in our model, and thus identified TGF alpha as a novel growth factor involved in OA. Further in vitro studies showed that TGF alpha treatment suppressed chondrocyte expression of the anabolic factors aggrecan and type II collagen and increased expression of the catabolic factor matrix metalloproteinase 13 (MMP13). The purpose of this study is to examine the requirement for TGF alpha in the progression of osteoarthritis in vivo. We hypothesize that Tgfa null mice will experience delayed OA progression compared to control littermates in a surgical disease model. Methods: Ten week old Tgfa null mice and their heterozygous littermates underwent meniscotibial transaction (MTX) of the left knee joint in order to create a mild form of degenerative disease. Mice from both groups also received sham surgery (capsulectomy). Seven weeks post-surgery, animals were sacrificed, and their knee joints were isolated and prepared for histology. Tissues were stained with safranin-O/fast green and joint histopathology was scored using the Osteoarthritis Research Society International (OARSI) criteria. Tissues were also immunostained for MMP13 expression. Results: Preliminary results show that MTX appears to produce a very mild form of degenerative joint disease while sham surgery shows no sign of disease at seven weeks-post surgery. Importantly, Tgfa null mice have lower OARSI scores and express less MMP13 than their heterozygous littermates at this time point. Conclusions: TGF alpha appears to play an important role in the progression of osteoarthritis in vivo. Future studies will examine the expression of additional anabolic and catabolic factors in Tgfa null joints as well as the potential role of TGF alpha in the cartilage growth plate.
IMPLEMENTATION OF A SCID ENGRAFTMENT MODEL WITH SYNOVIAL FIBROBLASTS AND CARTILAGE TO
Purpose: Patient heterogeneity is probably one of the reasons for failure of osteoarthritis (OA) clinical trials. We aim at identifying novel biomarkers and disease mechanism by focussing on adipose and synovial tissue from OA patients for improved patient stratification Methods: For this purpose, we implemented an engraftment model in the SCID mouse for in vivo characterization of synovial and adipose tissue from OA patients. The model was set up using synovial fibroblasts from rheumatoid arthritis (RA) patients that are known for their invasive behaviour. A sterile gelfoam sponge was seeded with synovial fibroblasts and co-implanted together with bovine cartilage. Evaluation of cartilage destruction and synoviocyte invasion was performed 60 days after implantation by H&E and safranine-O staining and compared with cartilage implanted with synovial fibroblasts from healthy donors. Results: Cartilage destruction and invasion of RA synovial fibroblast in the cartilage was observed.
Conclusions:
This model will be used to study the effects of adipose and synovial tissue from OA patients on cartilage integrity and invasive behaviour Purpose: Pain, morphological alterations and functional disability are cardinal features of the osteoarthritic (OA) joint. However, the relationship of joint structural damages to functional limb impairment remains to be clarified. This study aimed at investigating in an experimental canine anterior/cranial cruciate ligament (ACL)-induced instability model, the time-course of the relationship between some variables monitored with podobarometric gait analysis and the joint structural damages using magnetic resonance imaging (MRI). Methods: OA was surgically induced by transection of the right ACL in five dogs, which were subject to concurrent podobarometric gait analysis and MRI examinations prior to surgery (baseline), as well as 4, 8, and 26 weeks afterwards. The peak vertical force (PVF) and ground contact area (GCA) were measured, and ordinal scales were used to grade the cartilage defects, joint effusion, and osteophytosis found at MRI, as well as the subchondral bone marrow lesions (BML) assessed on T1GRE, T2wFS, and SPGR sequences. Changes in cartilage volume were quantified from computerized reconstruction. A mixed-effect general linear model for repeated measures with first-order autoregressive covariance structures was built for testing global mobility with ln (PVF), and a second one for testing gait changes with GCA. Time, the MRI variables, and selected dual interactions were added sequentially as fixed effects in both models, and GCA was an additional fixed-effect predictor of ln_(PVF). Both models were solved with maximum likelihood estimation at the 0,05 α-level.
Results: Following ACL section, limb impairment rapidly developed in all dogs, with PVF and GCA values dropping by week 4. After this acute disability phase, the dogs underwent a slow remission phase that was still incomplete by week 26. Prediction of PVF change was best estimated (R 2 =0.96) from GCA and BML-SPGR (p<0.0001), particularly during the phase of acute disability, whereas cartilage defect was more influential (R 2 =0.97) during the remission phase (p=0.0051) (week 8 to week 26). The other joint structural damages had insignificant effect on limb impairment and recovery. Both BML-SPGR and cartilage defect adversely affected the recovery in PVF, with mutually independent effects. Similar to ln_PVF, GCA showed an acute drop by week 4, followed afterwards by a remission phase (p<0.0001), which attained baseline values by week 26 (p=0,46) . The time-course of GCA recovery was negatively affected by cartilage defect, and was positively affected by joint effusion (p<0.0001 for both variables).
In recent human OA studies, pain and limb impairment were related mostly to BML and joint effusion. Our data from dogs with experimental OA confirms the role of BML and joint effusion on limb function. On one hand, BML and cartilage defect hinder the recovery of PVF. On the other hand, joint effusion positively influences GCA, supporting the existence of alleviating mechanisms that oppose to abnormal biomechanics. This study also clarifies the role of cartilage and other joint structural components in OA: cartilage volume and osteophytosis act as confounding factors with negligible role in limb impairment. Such structure/function modeling opens promising avenues for assessing outcome of disease-modifying OA drugs at the preclinical development stage. Purpose: The purpose of the study was to evaluate the efficacy of an ADAMTS-4 and ADAMTS-5 selective inhibitor in a robust animal model of osteoarthritis (OA). Methods: All animal studies were performed after IACUC approval. Male Lewis rats (20 per group) underwent medial meniscal tear surgery in the right knee joint 1 . Rats were treated twice daily by oral gavage with vehicle, selective ADAMTS-4/-5 inhibitor (ASI) (10, 30, or 100 mg/kg) or a broad-spectrum MMP inhibitor (30 mg/kg), All treatments were initiated 1 day before surgery and continued for 13 weeks. At the end of the dosing period, rats were evaluated for normal mobility and plasma was taken for pharmacokinetic analysis. Weight-bearing on the operated right leg and contra-lateral left leg was evaluated in the vehicle-treated and 30 mg/kg ASI-treated groups using an incapacitance meter, and expressed as grams difference in weight bearing between right and left leg. Following euthanasia, right knees were collected for histopathology evaluation including subjective and objective measures of cartilage degeneration and measures of joint capsule thickening. Results: Statistically significant decreases in cartilage degeneration scores and width of severe lesions were observed in animals treated with both 30 and 100 mg/kg BID ASI. No adverse events were observed in animals treated with any dose of ASI. Broadspectrum MMP inhibitor treatment resulted in decreased histologic evidence of cartilage degradation, but also caused a 40% thickening of the medial joint capsule, 6% lower body weight and a reluctance to mobilize. The vehicle-treated animals demonstrated a 27±2 grams decrease in weight bearing on the operated compared to the control limb, while the animals treated with 30 mg/kg SI had only a 16±2 grams decrease in weight bearing. This 41% increase in relative weight bearing on the unstable knee was statistically significant. Conclusions: This study demonstrated that the significant reduction in cartilage degradation following surgical induction of joint instability observed in gene-deleted ADAMTS-5 and ADAMTS-4/5 mice can also be produced by small molecule inhibition of enzyme activity. There were no adverse physiologic effects following systemic inhibition of ADAMTS-4/5 activity for 13 weeks. The normalization of weight-bearing, after treatment with an efficacious dose of ASI, indicated that decreasing cartilage degradation as a result of inhibition of Aggrecanase-mediated aggrecan degradation, positively affected stance and pain. These results support this strategy of selective ADAMTS-4/5 inhibition as a safe and effective method of disease modification and pain modification of osteoarthritis, and should be evaluated in the clinic.
SELECTIVE AGGRECANASE INHIBITION IS DISEASE MODIFYING AND PAIN ALLEVIATING IN A RAT MENISCAL
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